Non-severe | Severe | All patients | ||
---|---|---|---|---|
Characteristic – n (%) | 24 (68.6) | 11 (31.4) | 35 | P value |
Median age – years (IQR) | 58.9 (52.3, 67.5) | 52.0 (42.5, 63.6) | 57.1 (48.5, 66.6) | 0.256 |
Male sex – n (%) | 18 (75.0) | 7 (63.6) | 25 (71.4) | 0.490 |
Apical phenotype – n (%) | 4 (16.7) | 2 (18.2) | 6 (17.1) | 0.912 |
Risk factors for SCD | ||||
Sustained VT/VF – n (%) | 0 (0) | 1 (9.1) | 1 (2.9) | 0.134 |
Family history of SCD – n (%) | 2 (8.3) | 1 (9.1) | 3 (8.6) | 0.941 |
Wall thickness ≥30 mm – n (%) | 1 (4.2) | 1 (9.1) | 2 (5.7) | 0.560 |
Resting LVOT obstruction ≥30 mmHg – n (%) | 1 (4.2) | 3 (27.3) | 4 (11.4) | 0.046 |
Non-sustained VT – n (%) | 3 (12.5) | 0 (0) | 3 (8.6) | 0.220 |
Unexplained syncope – n (%) | 3 (12.5) | 1 (9.1) | 4 (11.4) | 0.769 |
Number of risk factors for SCD – n (%) | ||||
0 | 14 (58.3) | 5 (45.5) | 19 (54.3) | 0.296 |
1 | 10 (41.7) | 5 (45.5) | 15 (42.9) | |
2+ | 0 (0.0) | 1 (9.1) | 1 (2.9) | |
NYHA functional class – n (%) | ||||
I | 16 (66.7) | 8 (72.7) | 24 (68.6) | 0.720 |
II | 8 (33.3) | 3 (27.3) | 11 (31.4) | |
III | 0 (0) | 0 (0) | 0 (0) | |
IV | 0 (0) | 0 (0) | 0 (0) | |
Medications at baseline – n (%) | ||||
β-blocker | 14 (58.3) | 6 (54.6) | 20 (57.1) | 0.833 |
Ca2+-channel blocker | 0 (0) | 1 (9.1) | 1 (2.9) | 0.134 |